abstract |
The present invention relates to ulmoside A as a novel small molecule adiponectin receptor agonist useful for prevention or cure of metabolic diseases. The present invention further relates to the use of ulmoside-A (ULMA) ((2S,3S)-(+)-3',4',5,7-tetrahydroxydihydroflavonol-6-C-?-D-glucopyranoside) for alleviation, management or prevention or treatment of steroid-induced metabolic disorder. The present invention further relates to a pharmaceutical composition useful for prevention and/or treatment of various medical indications associated with metabolic diseases caused in humans and animals. |